-
A, B
Sequence alignment of miR‐183 and miR‐96 and their target sites in the 3′UTR of FoxO1 (A) or PDK4 (B) from various species.
-
C
Relative expression of miR‐183 and miR‐96 in C2C12 myocytes transfected with miR‐183 or miR‐96 agomir (left) (n = 3). Relative mRNA expression of FoxO1 and PDK4 in C2C12 cells treated with Ago‐183 or Ago‐96 (right) (n = 3).
-
D
Western blot analysis of FoxO1 and PDK4 in C2C12 cells treated with Ago‐183 or Ago‐96.
-
E
Relative expression of miR‐183 and miR‐96 in C2C12 myocytes transfected with miR‐183 or miR‐96 antagomir (left) (n = 3). Relative mRNA expression of FoxO1 and PDK4 in C2C12 cells treated with Ant‐183 or Ant‐96 (right) (n = 3).
-
F
Western blot analysis of FoxO1 and PDK4 in C2C12 cells treated with Ant‐183 or Ant‐96.
-
G, H
Sequence alignment of miR‐183 (G) and miR‐96 (H) and their target sites in the 3′UTR of ATGL from various species.
-
I, J
Relative mRNA expression (I, left) and Western blot analysis (J, top) of ATGL in C2C12 cells transfected with agomir for miR‐183 (Ago‐183) or miR‐96 (Ago‐96). Relative mRNA expression (I, right) and Western blot analysis (J, bottom) of ATGL in C2C12 cells transfected with antagomir for miR‐183 (Ant‐183) or miR‐96 (Ant‐96). (n = 5 per group for RT–PCR analysis).
-
K
Relative mRNA expression of ATGL and Western blot analysis of FoxO1 and ATGL in C2C12 cells transfected with Ago‐183/96 and FoxO1 as indicated (n = 3).